Analysts Cut Targets for Sarepta, Korro Bio, Beyond Meat

Recent analyst reports show widespread price target reductions for Sarepta Therapeutics, Korro Bio, and Beyond Meat amid sector-wide challenges. Sarepta faced target cuts from several analysts following disappointing Elevidys sales, a patient death, and increased regulatory scrutiny under new FDA leadership. Despite these setbacks, some analysts maintain Buy ratings on Sarepta, citing strong liquidity and fundamental value. Korro Bio's target was reduced by H.C. Wainwright due to rising competition and a 20% workforce reduction to preserve cash. Beyond Meat saw its price target slashed by TD Cowen after missing Q1 expectations, withdrawing 2025 guidance, and taking on costly loans to address liquidity issues. These moves underscore operational, regulatory, and financial pressures across both the biotech and plant-based food industries.